Navigation Links
Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
Date:1/7/2008

Ortho-McNeil to Continue Investigation of GDIR Agonists Under its

Partnership with Arena

SAN DIEGO, Jan. 7 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that initial clinical study results for APD668, an oral drug candidate discovered by Arena and being investigated for the treatment of type 2 diabetes under a partnership with Ortho-McNeil Pharmaceutical, Inc., suggest that Glucose-Dependent Insulinotropic Receptors, or GDIRs, may improve glucose control in patients with type 2 diabetes.

Ortho-McNeil's initial clinical studies evaluated healthy volunteers and patients with type 2 diabetes in randomized, double-blind, placebo-controlled trials evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple (14 day) escalating doses of APD668. Based on the data from those studies, Ortho-McNeil has decided to put APD668 on hold and has advanced a potentially more potent Arena discovered GDIR agonist into preclinical development.

"We are encouraged by the clinical study results supporting GDIR agonists as effective modulators of glucose homeostasis in patients with type 2 diabetes, and we look forward to the results of Ortho-McNeil advancing another of Arena's GDIR compounds into development," stated Dominic P. Behan, Ph.D., Arena's Senior Vice President and Chief Scientific Officer.

About the Glucose-Dependent Insulinotropic Receptor (GDIR)

The GDIR is an orphan G protein-coupled receptor, or GPCR, discovered by Arena. It is expressed in beta cells, the cells in the pancreas responsible for producing insulin in response to increases in blood glucose. Stimulation of the GDIR is intended to more efficiently
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
2. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
3. Fovea Pharmaceuticals Receives Orphan Drug Designation from EC for RdCVF for the Treatment of Retinitis Pigmentosa
4. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
5. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
6. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
7. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
8. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
9. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
10. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
11. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... -- ResMed Inc. (NYSE: RMD ) today announced results ... June 30, 2014.  Revenue for the quarter was $415.2 million, ... 1 percent decrease on a constant currency basis). Net income ... the quarter ended June 30, 2013. Diluted earnings per share ... compared to the quarter ended June 30, 2013.  ...
(Date:7/31/2014)... FRANCISCO, July 31, 2014 Nektar Therapeutics (Nasdaq: ... second quarter ended June 30, 2014. Cash ... $301.4 million as compared to $309.1 million at March 31, ... for Nektar as we look forward to significant milestones for ... Robin, President and Chief Executive Officer of Nektar. "The first ...
(Date:7/31/2014)... , July 31, 2014  Decision ... changes brought about by the Affordable Care ... and prescribing of pharmaceutical therapies. The ACA ... beneficiaries through new regulations and expanded access ... in the health exchanges—state-based marketplaces set up ...
Breaking Medicine Technology:RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 2Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 3Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 4Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 5Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 7Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 8Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 9Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 10Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 11Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 12Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 13Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 14Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 2Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 4
... ROCHESTER HILLS, Mich., Jan. 8 CSG/SportsCoatings,today announced ... will,be treated with its industry-leading antimicrobial coating, TurfAide(TM),in ... in 2007., The exponential increase in demand ... a 2007 report in the Journal of the ...
... of Phase 2 Clinical Trials in ... ... a privately held,biotechnology company developing treatments for metabolic diseases,announced today that it ... the use of very low dose glucagon, or DIO-901, in,the prevention of ...
Cached Medicine Technology:10 Million Square Feet of Turf Set to be Treated in 2008 in Response to MRSA Outbreaks Nationwide 2DiObex, Inc. Awarded Patent for the Prevention of Insulin-Induced Hypoglycemia 2
(Date:7/31/2014)... Ohio (PRWEB) July 31, 2014 United ... at 9 a.m. on Monday, September 15, with its ... Methodist Church, 3440 Shroyer Rd., Kettering, OH. Dr. ... Counseling in the Emma Toussant Chair will speak on ... , Dr. Justes’ teaching and research interests include pastoral ...
(Date:7/31/2014)... July 31, 2014 In today’s world, a ... to get. Snoring and sleep apnea (a medical problem where ... and their bed partners of the rest they need to ... the population snores and 20 million people in the United ... been diagnosed and treated; and of those treated, many cannot ...
(Date:7/31/2014)... Hook Your Ex, a system created by Steve Pratt, who discovered ... their partner, to the point of starvation, that they come back ... taught to hundreds of men and women across the country with ... , Shane Michaels agrees this simple trick is genius and can ... chance at getting back together with their ex. “I was ...
(Date:7/31/2014)... NEWwoodworks, fine woodworking group at New Energy ... a website dedicated to highlighting their craft and their ... handcrafted cabinetry, furniture, stairs , doors, and other ... for taking on the remarkable, challenging projects that few ... reclaimed wood, often using near extinct species such as ...
(Date:7/31/2014)... CA (PRWEB) July 31, 2014 Dr. ... scientific meetings, “I love the experience of traveling and ... our centers in Southern California. We are now ... few years ago. It is our pleasure to communicate ... presentation about more efficient ways of performing FUE transplantation ...
Breaking Medicine News(10 mins):Health News:United Theological Seminary to Open 144th Year 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Hook Your Ex Review by Shane Michaels Exposes Steve Pratt And His New Method For Getting Back With The Ex 2Health News:NEWwoodworks Fine Woodworking Group Launches New Website 2Health News:NEWwoodworks Fine Woodworking Group Launches New Website 3Health News:Los Angles Hair Transplant Surgeon, Dr. Parsa Mohebi Inspires Doctors at Global Conferences to Adopt His Novel Method in FUE Hair Transplantation 2
... Mich. - A cancer diagnosis affects more than just the ... Michigan Comprehensive Cancer Center finds spouses report similar physical and ... study found that what really impacted emotional distress - among ... was newly diagnosed, facing a recurrence or living with advanced ...
... Board established; Former URAC CEO joins company along with ... Chief Medical Officer, ... of key senior management leaders to head the,growing healthcare consulting and technology ... and CEO; -- Joel V. Brill, MD, AGAF FASGE FACG ...
... research that aligns patients and treatments., ... The,H. Lee Moffitt Cancer Center & ... health enterprise platform, to aid in its,development ... be used,to assimilate large quantities of diverse ...
... MEDIA, Pa., Sept. 20 Synova Healthcare Group,Inc. (OTC ... sale,of approximately $3.3 million in aggregate notional principal amount ... September 19, 2012,and related common stock purchase warrants. This ... private placement of notes and warrants in the,aggregate notional ...
... 2007 Breihan Bridgewater suffers from emphysema. He sleeps on ... it feels like theres a boulder resting on his chest. ... prostate cancer, the thought of undergoing surgery or having to ... treatments left him with an uneasy feeling and a ...
... is leading cause of inherited mental retardation , , THURSDAY, ... defect might be a target for the treatment of ... researchers report. , The discovery in rats provides an ... condition changes the way brain cells communicate, according to ...
Cached Medicine News:Health News:Cancer patients, spouses report similar emotional distress, U-M study finds 2Health News:Schooner Healthcare Services, LLC Announces New Leadership Team 2Health News:Moffitt Selects Microsoft's Azyxxi to Help Drive Personalized Cancer Treatment 2Health News:Synova Completes Sale of $3.3 Million in Senior Convertible Notes and Warrants 2Health News:Synova Completes Sale of $3.3 Million in Senior Convertible Notes and Warrants 3Health News:Radiation therapy technique reduces length of prostate cancer treatment 2Health News:Radiation therapy technique reduces length of prostate cancer treatment 3Health News:Brain Defect Helps Drive Fragile X Syndrome 2Health News:Brain Defect Helps Drive Fragile X Syndrome 3
... Final Flexion Wraps restore full PIP joint ... when lost due to arthritic changes. Unparalleled ... material hugs the finger to prevent slipping ... motion. One size. Sold in packages of ...
One splint does it all....
... of minor knee pain like arthritis, tendonitis ... with the motion of the knee, applying ... tendon and assisting in the relief of ... with high density foam padding molds itself ...
... braces are designed to provide comfortable stabilization ... and versatile, ROM braces are an easy ... The braces are extremely patient-friendly, too. , ... hinges that allow you to restrict extension ...
Medicine Products: